A long-term safety trial to investigate the safety of intermittent use of AN 2728 ointment 2% for up to 12 months

Trial Profile

A long-term safety trial to investigate the safety of intermittent use of AN 2728 ointment 2% for up to 12 months

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Mar 2016

At a glance

  • Drugs Crisaborole (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions
  • Sponsors Anacor Pharmaceuticals
  • Most Recent Events

    • 22 Mar 2016 According to an Anacor Pharmaceuticals media release, the US FDA has accepted for review New Drug Application (NDA) seeking approval of crisaborole topical ointment 2% for the treatment of mild-to-moderate atopic dermatitis in children and adults with PDUFA date of January 7, 2017.
    • 23 Feb 2016 According to an Anacor pharmaceuticals media release, the company will present phase III trial data of crisaborole 2% topical ointment for the treatment of mild to moderate atopic dermatitis at 74th Annual Meeting of the American Academy of Dermatology
    • 07 Jan 2016 Results published in Anacor pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top